Network meta-analysis treatment ranking results for pain outcome analyses, for each of short-term outcomes, medium-term outcomes and long-term outcomes
| Treatment | Short-term pain | Medium-term pain | Long-term pain | |||
| SUCRA | Mean rank | SUCRA | Mean rank | SUCRA | Mean rank | |
| ESWT | 60.7 | 3.8 | 67.2 | 3.6 | 54.5 | 4.2 |
| ESWT+Exe | 29.4 | 6.6 | 64.2 | 3.5 | ||
| ESWT+Orthoses | 66.5 | 3.3 | 80.3 | 2.6 | ||
| Exe | 24.6 | 6.3 | 26.1 | 6.9 | 61.4 | 3.7 |
| NSAID Inj+Exe | 63.3 | 3.6 | ||||
| Oral NSAID | 3.7 | 7.7 | 13.3 | 7.9 | ||
| Orthoses | 60.5 | 3.8 | 66.6 | 3.7 | 20 | 6.6 |
| Placebo | 30.1 | 5.9 | 48.7 | 5.1 | 15.6 | 6.9 |
| Steroid Inj | 79.5 | 2.4 | 63.7 | 3.9 | 58.4 | 3.9 |
| Steroid Inj+Exe | 74.4 | 2.8 | 54.7 | 4.6 | 62.7 | 3.6 |
Surface under cumulative ranking curve (SUCRA) values (0 – 100) and mean ranks are presented, based on a simulation with 1000 replications. Higher SUCRA s and lower mean ranks indicate better performing treatments.
ESWT, extracorporeal shockwave therapy; ESWT+Exe, extracorporeal shockwave therapy combined with exercise; ESWT+Orthoses, extracorporeal shockwave therapy combined with orthoses; Exe, exercise; NSAID Inj+Exe, oral non-steroidal anti-inflammatory drug combined with exercise; Oral NSAID, oral non-steroidal anti-inflammatory drug; Orthoses, prefabricated or customised foot orthoses; Placebo, usual care/placebo; Steroid Inj, corticosteroid injection; Steroid Inj+Exe, corticosteroid injection combined with exercise.